Levodopa/Carbidopa Orion (Carbidopa, Levodopa)

Levodopa serves as a dopamine precursor that crosses the blood‑brain barrier and is converted to dopamine in the central nervous system. Carbidopa blocks peripheral conversion of levodopa, increasing the amount that reaches the brain and reducing peripheral side effects.

The dosage of Levodopa/Carbidopa Orion is individualized. A qualified prescriber determines the appropriate strength, frequency, and titration schedule based on the patient’s clinical condition, response, and tolerability.

Safety data are limited. Levodopa/Carbidopa should be used during pregnancy or lactation only if the potential benefits justify the possible risks to the fetus or infant. Consultation with a healthcare professional is essential.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Levodopa/Carbidopa is considered the most effective oral therapy for symptomatic control of Parkinson’s disease. Compared with dopamine agonists, it generally provides stronger motor improvement but may have a higher risk of dyskinesia. It is often used as first‑line therapy or in combination with other agents.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Levodopa/Carbidopa Orion is taken orally, usually with a glass of water. It may be taken with or without food, but high‑protein meals can affect absorption, so spacing the dose from protein‑rich meals is often recommended.

Serious risks include the development of dyskinesia (involuntary movements), neuropsychiatric effects such as hallucinations or psychosis, severe orthostatic hypotension, and, rarely, neuroleptic malignant syndrome. Prompt medical evaluation is required if any of these occur.

Patients with known hypersensitivity to levodopa, carbidopa, or any excipients should avoid the product. It is also contraindicated in individuals taking non‑selective MAO inhibitors. Caution is advised in patients with cardiovascular disease, severe liver impairment, or a history of psychiatric disorders.